- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02000167
Mitochondrial Dysfunction in Phelan-McDermid Syndrome
Mitochondrial Dysfunction in Phelan-McDermid Syndrome: Explaining Clinical Variation and Providing a Path Towards Treatment
Study Overview
Status
Conditions
Detailed Description
Phelan-McDermid Syndrome (PMS) results from a deletion within the 22q13 chromosome region. Most children have specific physical morphology and developmental delays with many displaying characteristics of autism spectrum disorder (ASD) including abnormalities in social development. The behavioral aspect of PMS that parallels ASD has raised particular interest as the SHANK3 gene, which lies in the 22q13 region, is important for synaptic development, and animal SHANK3 knockout models demonstrate ASD characteristics thereby confirming the importance of this gene in PMS. However, despite the importance of the SHANK3 gene, individuals with PMS have variations in their development, behavior and medical characteristics that cannot be fully explained by the SHANK3 deletion.
Recently, Frye (2012) has noted the existence of 6 mitochondrial genes that lie slightly proximal to the SHANK3 gene within the 22q13 region. These include genes important electron transport change function (SCO2, NDUFA6), mitochondrial DNA (TYMP) and RNA (TRMU) metabolism, fatty acid metabolism (CPT1B) and tricarboxylic acid cycle function (ACO2). Since most Individuals with PMS have deletions that include chromosomal deletion outside of the SHANK3 region, it is very likely that many, if not most, of children with PMS may have deletions in these mitochondrial genes. Many of these genes have been linked to mitochondrial disease, even in the heterozygous state. Even if recognized, mitochondrial disease is only linked to a homozygous abnormal state (autosomal recessive), the loss of one gene (heterozygous state) could result in symptomatology when associated with deletions in other mitochondrial or non-mitochondrial genes. Abnormalities in mitochondrial pathways can result in neurologic and non-neurologic symptoms including those sometimes seen in children with PMS. Added with the SHANK3 deletion, abnormalities in these mitochondrial genes could explain variations in patterns of development and the eventual cognitive potential.
References: Frye RE. Mitochondrial disease in 22q13 duplication syndrome. J Child Neurol. 2012; 27(7):942-9.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- Arkansas Children's Hospital Research Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- 1-21 years of age
- Diagnosed with Phelan-McDermid Syndrome AND diagnosed with Mitochondrial Disorder
- Diagnosed with Phelan-McDermid Syndrome
Exclusion Criteria:
- none
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
Phelan-McDermid Syndrome only
Diagnosed with Phelan-McDermid Syndrome; 50 subjects to be recruited.
1-21 years of age
|
Co-morbid Phelan-McDermid Syndrome & Mitochodrial Disorder
1-21 years of age; Diagnosed with Phelan-McDermid Syndrome AND diagnosed with Mitochondrial Disorder; 50 subjects to be recruited.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Electron Transport Chain function derived from buccal cells of known PMS patients
Time Frame: Up to two years
|
Electron transport chain (ETC) function will be measured in cells collected using Buccal swabs to determine if certain PMS patients symptomatology and clinical characteristics/variations can be explained due to variations in patterns of ETC function in this cohort
|
Up to two years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Richard E Frye, M.D./Ph.D., University of Arkansas for Medical Sciences; Arkansas Children's Hospital Research Institute
- Principal Investigator: Michael J Goldenthal, Ph.D., Drexel University College of Medicine
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 136271
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Phelan-McDermid Syndrome
-
Swathi SethuramCompletedPhelan McDermid SyndromeUnited States
-
Assistance Publique - Hôpitaux de ParisRecruitingAutism Spectrum DisorderFrance
-
Affiliated Hospital of Jiangnan UniversityCompletedGrowth Hormone Treatment | Phelan-McDermid SyndromeChina
-
Neuren Pharmaceuticals LimitedActive, not recruitingPhelan-McDermid SyndromeUnited States
-
Alexander KolevzonCompletedPhelan-McDermid SyndromeUnited States
-
Icahn School of Medicine at Mount SinaiNational Institute of Mental Health (NIMH)CompletedPhelan-McDermid Syndrome | 22q13 Deletion SyndromeUnited States
-
Alexander KolevzonCompletedEpilepsy | Phelan-McDermid SyndromeUnited States
-
Boston Children's HospitalPhelan-McDermid Syndrome FoundationCompletedIntellectual Disability | Autism Spectrum Disorder | Phelan-McDermid SyndromeUnited States
-
Antonio PersicoUniversity of Bari; Associazione Italiana Sindrome di Phelan-McDermid (AISPHEM)Enrolling by invitationAutism Spectrum Disorder | Phelan-McDermid SyndromeItaly
-
Boston Children's HospitalEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingIntellectual Disability | Autism Spectrum Disorder | Phelan-McDermid SyndromeUnited States